Dr. Jagannath on HDAC Inhibitors for Multiple Myeloma

Sundar Jagannath, MD
Published: Wednesday, Feb 29, 2012

Sundar Jagannath, MD, director of the Multiple Myeloma Program at the Tisch Cancer Institute at Mount Sinai Medical Center in New York City, discusses the clinical trials that combined histone deacetylase (HDAC) inhibitors to bortezomib (Velcade) in patients with relapsed or refractory multiple myeloma.

Vorinostat (Zolinza) is the first HDAC inhibitor to go through an international phase III trial and demonstrated an improvement in progression-free survival when combined with bortzezomib. Results from the trial were presented at the 2011 ASH meeting in San Diego. Another pan-DAC inhibitor named panobinostat has also been investigated in combination with bortezomib. Results for this agent showed similar efficacy to vorinostat.

HDAC inhibitors represent a new class of drugs for multiple myeloma patients. Expanding the treatment armamentarium by adding this new class of drugs provides more opportunities for patients. Jagannath explains that physicians are anxious to receive further results on the addition of these new agents.

Sundar Jagannath, MD, director of the Multiple Myeloma Program at the Tisch Cancer Institute at Mount Sinai Medical Center in New York City, discusses the clinical trials that combined histone deacetylase (HDAC) inhibitors to bortezomib (Velcade) in patients with relapsed or refractory multiple myeloma.

Vorinostat (Zolinza) is the first HDAC inhibitor to go through an international phase III trial and demonstrated an improvement in progression-free survival when combined with bortzezomib. Results from the trial were presented at the 2011 ASH meeting in San Diego. Another pan-DAC inhibitor named panobinostat has also been investigated in combination with bortezomib. Results for this agent showed similar efficacy to vorinostat.

HDAC inhibitors represent a new class of drugs for multiple myeloma patients. Expanding the treatment armamentarium by adding this new class of drugs provides more opportunities for patients. Jagannath explains that physicians are anxious to receive further results on the addition of these new agents.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Expert Insights on the Management of Myeloproliferative Neoplasms: Evidence-based Approaches and Emerging Strategies to Address Challenges in CareSep 29, 20181.5
1st Annual LIVE Medical Crossfire®: Expert Exchanges in Hematologic Malignancies OnlineSep 30, 20188.0
Publication Bottom Border
Border Publication
x